NASDAQ:EPIX - ESSA Pharma Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ESSA Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.50 +0.25 (+4.76 %) (As of 02/19/2020 04:00 PM ET) Add Compare Today's Range$5.13Now: $5.50▼$5.5050-Day Range$5.25MA: $5.58▼$5.8752-Week Range$1.41Now: $5.50▼$6.14Volume191,660 shsAverage Volume29,443 shsMarket Capitalization$114.18 millionP/E RatioN/ADividend YieldN/ABeta2.01 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ESSA Pharma Inc, a pharmaceutical company, focuses on the development of small molecule drugs for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPIX Previous Symbol CUSIPN/A CIK1633932 Webhttp://www.essapharma.com/ Phone778-331-0962Debt Debt-to-Equity RatioN/A Current Ratio9.74 Quick Ratio9.74Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.37 per share Price / Book2.32Profitability EPS (Most Recent Fiscal Year)($1.46) Net Income$-10,440,000.00 Net MarginsN/A Return on Equity-68.43% Return on Assets-51.20%Miscellaneous Employees15 Outstanding Shares20,760,000Market Cap$114.18 million Next Earnings Date5/8/2020 (Estimated) OptionableNot Optionable Receive EPIX News and Ratings via Email Sign-up to receive the latest news and ratings for EPIX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EPIX Rates by TradingView ESSA Pharma (NASDAQ:EPIX) Frequently Asked Questions What is ESSA Pharma's stock symbol? ESSA Pharma trades on the NASDAQ under the ticker symbol "EPIX." How were ESSA Pharma's earnings last quarter? ESSA Pharma Inc (NASDAQ:EPIX) announced its quarterly earnings results on Thursday, February, 13th. The company reported ($0.22) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.18) by $0.05. View ESSA Pharma's Earnings History. When is ESSA Pharma's next earnings date? ESSA Pharma is scheduled to release their next quarterly earnings announcement on Friday, May 8th 2020. View Earnings Estimates for ESSA Pharma. What price target have analysts set for EPIX? 2 Wall Street analysts have issued 12 month price objectives for ESSA Pharma's shares. Their forecasts range from $8.00 to $8.00. On average, they expect ESSA Pharma's stock price to reach $8.00 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View Analyst Price Targets for ESSA Pharma. What is the consensus analysts' recommendation for ESSA Pharma? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ESSA Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ESSA Pharma. What are Wall Street analysts saying about ESSA Pharma stock? Here are some recent quotes from research analysts about ESSA Pharma stock: 1. According to Zacks Investment Research, "ESSA Pharma Inc. is a pharmaceutical company. The company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA Pharma Inc. is based in Vancouver, Canada. " (5/22/2019) 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $14 price target. Our price target is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our current target is based 100% on the projected lead Aniten asset for prostate cancer. Factors that could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (5/17/2019) Has ESSA Pharma been receiving favorable news coverage? Media coverage about EPIX stock has trended extremely positive this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ESSA Pharma earned a media sentiment score of 5.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for ESSA Pharma. Are investors shorting ESSA Pharma? ESSA Pharma saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 84,800 shares, a decrease of 8.3% from the January 15th total of 92,500 shares. Based on an average daily trading volume, of 40,400 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.6% of the company's stock are sold short. View ESSA Pharma's Current Options Chain. Who are some of ESSA Pharma's key competitors? Some companies that are related to ESSA Pharma include Innate Pharma (IPHYF), Fulcrum Therapeutics (FULC), OrganiGram (OGI), Xenon Pharmaceuticals (XENE), Beyondspring (BYSI), Organogenesis (ORGO), Dynavax Technologies (DVAX), ProQR Therapeutics (PRQR), Recro Pharma (REPH), Cue Biopharma (CUE), AnaptysBio (ANAB), Avid Bioservices (CDMO), Avedro (AVDR), Calithera Biosciences (CALA) and Mallinckrodt (MNK). What other stocks do shareholders of ESSA Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other ESSA Pharma investors own include REDHILL BIOPHAR/S (RDHL), Aurinia Pharmaceuticals (AUPH), Trevena (TRVN), Lipocine (LPCN), Protalix Biotherapeutics (PLX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Biopharmx (BPMX), Agile Therapeutics (AGRX) and BIOLINERX LTD/S (BLRX). Who are ESSA Pharma's key executives? ESSA Pharma's management team includes the folowing people: Dr. David Ross Parkinson, Pres, CEO & Director (Age 69)Mr. David S. Wood, Chief Financial Officer (Age 62)Mr. Peter A. Virsik, Exec. VP & COO (Age 48)Dr. Raymond Andersen, CTO, Sec. & Director (Age 72)Dr. Marianne D. Sadar, Chief Scientific Officer & Director (Age 58) Who are ESSA Pharma's major shareholders? ESSA Pharma's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.06%) and Advisor Group Inc. (0.04%). Which major investors are buying ESSA Pharma stock? EPIX stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Advisor Group Inc.. How do I buy shares of ESSA Pharma? Shares of EPIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is ESSA Pharma's stock price today? One share of EPIX stock can currently be purchased for approximately $5.50. How big of a company is ESSA Pharma? ESSA Pharma has a market capitalization of $114.18 million. The company earns $-10,440,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. ESSA Pharma employs 15 workers across the globe.View Additional Information About ESSA Pharma. What is ESSA Pharma's official website? The official website for ESSA Pharma is http://www.essapharma.com/. How can I contact ESSA Pharma? ESSA Pharma's mailing address is 999 WEST BROADWAY SUITE 720, VANCOUVER A1, V5Z 1K5. The company can be reached via phone at 778-331-0962 or via email at [email protected] MarketBeat Community Rating for ESSA Pharma (NASDAQ EPIX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 311 (Thanks for Voting!)Underperform Votes: 210 (Thanks for Voting!)Total Votes: 521MarketBeat's community ratings are surveys of what our community members think about ESSA Pharma and other stocks. Vote "Outperform" if you believe EPIX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPIX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2020 by MarketBeat.com StaffFeatured Article: What is a Tariff?
